IOL Chemicals and Pharmaceuticals Gelecekteki Büyüme

Future kriter kontrolleri 4/6

IOL Chemicals and Pharmaceuticals kazanç ve gelirin sırasıyla yıllık 29.2% ve 10.6% oranında artacağı tahmin edilmektedir. EPS'nin yıllık 29.2% oranında büyümesi beklenmektedir. Özkaynak kârlılığının 3 yıl içinde 10.5% olacağı tahmin edilmektedir.

Anahtar bilgiler

29.2%

Kazanç büyüme oranı

29.2%

EPS büyüme oranı

Pharmaceuticals kazanç büyümesi	17.5%
Gelir büyüme oranı	10.6%
Gelecekteki özkaynak getirisi	10.5%
Analist kapsamı	Low
Son güncelleme	20 Jan 2025

Gelecekteki son büyüme güncellemeleri

Recent updates

Investors Still Aren't Entirely Convinced By IOL Chemicals and Pharmaceuticals Limited's (NSE:IOLCP) Earnings Despite 26% Price Jump

Dec 20

IOL Chemicals and Pharmaceuticals (NSE:IOLCP) Has A Somewhat Strained Balance Sheet

Nov 19

A Piece Of The Puzzle Missing From IOL Chemicals and Pharmaceuticals Limited's (NSE:IOLCP) Share Price

Sep 11

Is There An Opportunity With IOL Chemicals and Pharmaceuticals Limited's (NSE:IOLCP) 34% Undervaluation?

Jun 12

Is IOL Chemicals and Pharmaceuticals (NSE:IOLCP) Using Too Much Debt?

Aug 30

IOL Chemicals and Pharmaceuticals (NSE:IOLCP) Has A Pretty Healthy Balance Sheet

May 18

IOL Chemicals and Pharmaceuticals (NSE:IOLCP) Will Pay A Dividend Of ₹4.00

Feb 10

Is IOL Chemicals and Pharmaceuticals (NSE:IOLCP) Using Too Much Debt?

Jun 07

Calculating The Intrinsic Value Of IOL Chemicals and Pharmaceuticals Limited (NSE:IOLCP)

May 07

Do IOL Chemicals and Pharmaceuticals's (NSE:IOLCP) Earnings Warrant Your Attention?

May 04

Is IOL Chemicals and Pharmaceuticals Limited (NSE:IOLCP) An Attractive Dividend Stock?

Mar 13

Is IOL Chemicals and Pharmaceuticals (NSE:IOLCP) Using Too Much Debt?

Feb 23

Should You Rely On IOL Chemicals and Pharmaceuticals' (NSE:IOLCP) Earnings Growth?

Feb 08

IOL Chemicals and Pharmaceuticals Limited's (NSE:IOLCP) Recent Stock Performance Looks Decent- Can Strong Fundamentals Be the Reason?

Jan 27

How Does IOL Chemicals and Pharmaceuticals' (NSE:IOLCP) CEO Salary Compare to Peers?

Jan 15

Estimating The Intrinsic Value Of IOL Chemicals and Pharmaceuticals Limited (NSE:IOLCP)

Jan 02

Shareholders of IOL Chemicals and Pharmaceuticals (NSE:IOLCP) Must Be Delighted With Their 869% Total Return

Dec 21

Is Now The Time To Put IOL Chemicals and Pharmaceuticals (NSE:IOLCP) On Your Watchlist?

Dec 09

These 4 Measures Indicate That IOL Chemicals and Pharmaceuticals (NSE:IOLCP) Is Using Debt Reasonably Well

Nov 24

IOL Chemicals and Pharmaceuticals (NSE:IOLCP) Could Be A Buy For Its Upcoming Dividend

Nov 12

Is There More To The Story Than IOL Chemicals and Pharmaceuticals's (NSE:IOLCP) Earnings Growth?

Nov 09

Will Weakness in IOL Chemicals and Pharmaceuticals Limited's (NSE:IOLCP) Stock Prove Temporary Given Strong Fundamentals?

Oct 27

Here's What We Think About IOL Chemicals and Pharmaceuticals' (NSE:IOLCP) CEO Pay

Oct 09

Calculating The Fair Value Of IOL Chemicals and Pharmaceuticals Limited (NSE:IOLCP)

Sep 18

Here's Why I Think IOL Chemicals and Pharmaceuticals (NSE:IOLCP) Might Deserve Your Attention Today

Sep 03

Cautious Investors Not Rewarding IOL Chemicals and Pharmaceuticals Limited's (NSE:IOLCP) Performance Completely

Aug 16

Kazanç ve Gelir Büyüme Tahminleri

NSEI:IOLCP - Analistlerin gelecek tahminleri ve geçmiş finansal verileri (INR Millions )
Tarih	Gelir	Kazançlar	Serbest Nakit Akışı	Faaliyetlerden Nakit	Avg. Analist Sayısı
3/31/2027	26,731	2,168	N/A	2,934	1
3/31/2026	24,980	1,911	39	2,280	2
3/31/2025	22,547	1,460	377	1,950	2
9/30/2024	20,524	998	-1,586	1,273	N/A
6/30/2024	20,720	1,185	N/A	N/A	N/A
3/31/2024	21,328	1,344	159	2,901	N/A
12/31/2023	22,161	1,716	N/A	N/A	N/A
9/30/2023	22,192	1,723	62	2,582	N/A
6/30/2023	22,153	1,503	N/A	N/A	N/A
3/31/2023	22,171	1,391	-895	1,223	N/A
12/31/2022	22,024	1,041	N/A	N/A	N/A
9/30/2022	22,341	1,204	-538	824	N/A
6/30/2022	22,305	1,353	N/A	N/A	N/A
3/31/2022	21,840	1,677	-602	931	N/A
12/31/2021	20,719	2,132	N/A	N/A	N/A
9/30/2021	20,298	2,879	703	2,228	N/A
6/30/2021	20,254	3,840	N/A	N/A	N/A
3/31/2021	19,670	4,446	2,716	3,798	N/A
12/31/2020	19,481	4,596	N/A	N/A	N/A
9/30/2020	19,463	4,428	2,902	3,779	N/A
6/30/2020	18,618	4,035	N/A	N/A	N/A
3/31/2020	18,945	3,613	3,905	4,708	N/A
12/31/2019	18,753	3,727	N/A	N/A	N/A
9/30/2019	18,423	3,569	N/A	N/A	N/A
6/30/2019	18,163	3,076	N/A	N/A	N/A
3/31/2019	16,853	2,367	2,126	2,732	N/A
12/31/2018	15,506	1,465	N/A	N/A	N/A
9/30/2018	13,350	731	N/A	N/A	N/A
6/30/2018	11,298	391	N/A	N/A	N/A
3/31/2018	9,833	277	N/A	1,197	N/A
12/31/2017	8,891	178	N/A	N/A	N/A
9/30/2017	8,094	100	N/A	N/A	N/A
6/30/2017	8,265	65	N/A	N/A	N/A
3/31/2017	7,107	47	N/A	833	N/A
12/31/2016	6,595	39	N/A	N/A	N/A
9/30/2016	6,197	-74	N/A	N/A	N/A
6/30/2016	6,055	-214	N/A	N/A	N/A
3/31/2016	5,804	-400	N/A	177	N/A
12/31/2015	5,131	-692	N/A	N/A	N/A
9/30/2015	4,377	-890	N/A	N/A	N/A
6/30/2015	4,008	-858	N/A	N/A	N/A
3/31/2015	3,847	-667	N/A	-470	N/A
12/31/2014	4,405	-378	N/A	N/A	N/A
9/30/2014	5,115	-71	N/A	N/A	N/A
6/30/2014	5,452	37	N/A	N/A	N/A
3/31/2014	5,635	33	N/A	784	N/A

Analist Gelecek Büyüme Tahminleri

Kazançlar ve Tasarruf Oranları: IOLCP 'nin tahmini kazanç büyümesi (yıllık 29.2% ) tasarruf oranının ( 6.7% ) üzerindedir.

Kazançlar ve Piyasa: IOLCP şirketinin kazançlarının (yıllık 29.2% ) Indian pazarından (yıllık 17.8% ) daha hızlı büyümesi öngörülüyor.

Yüksek Büyüme Kazançları: IOLCP şirketinin kazançlarının önümüzdeki 3 yıl içerisinde önemli ölçüde artması bekleniyor.

Gelir ve Pazar: IOLCP şirketinin gelirinin (yıllık 10.6% ) Indian pazarından (yıllık 10.6% ) daha hızlı büyümesi öngörülüyor.

Yüksek Büyüme Geliri: IOLCP şirketinin gelirinin (yıllık 10.6% ) yıllık 20% oranından daha yavaş büyümesi öngörülüyor.

Hisse Başına Kazanç Büyüme Tahminleri

Gelecekteki Özkaynak Getirisi

Gelecekteki ROE: IOLCP 'nin Özsermaye Getirisi'nin 3 yıl içinde düşük olması tahmin ediliyor ( 10.5 %).

Büyüyen şirketleri keşfedin

Şirket Analizi ve Finansal Veri Durumu

Veri	Son Güncelleme (UTC saati)
Şirket Analizi	2025/01/23 06:38
Gün Sonu Hisse Fiyatı	2025/01/23 00:00
Kazançlar	2024/09/30
Yıllık Kazançlar	2024/03/31

Veri Kaynakları

Şirket analizimizde kullanılan veriler S&P Global Market Intelligence LLC'den alınmıştır. Bu raporu oluşturmak için analiz modelimizde aşağıdaki veriler kullanılmıştır. Veriler normalize edilmiştir, bu da kaynağın mevcut olmasından kaynaklanan bir gecikmeye neden olabilir.

Paket	Veri	Zaman Çerçevesi	Örnek ABD Kaynağı ^*
Şirket Finansalları	10 yıl	Gelir tablosu Nakit akış tablosu Bilanço	SEC Form 10-K SEC Form 10-Q
Analist Konsensüs Tahminleri	+3 yıl	Finansal tahminler Analist fiyat hedefleri	Analist Araştırma Raporları Blue Matrix
Piyasa Fiyatları	30 yıl	Hisse senedi fiyatları Temettüler, Bölünmeler ve Eylemler	ICE Piyasa Verileri SEC Form S-1
Sahiplik	10 yıl	En büyük hissedarlar İçeriden öğrenenlerin ticareti	SEC Form 4 SEC Form 13D
Yönetim	10 yıl	Liderlik ekibi Yönetim Kurulu	SEC Form 10-K SEC Form DEF 14A
Önemli Gelişmeler	10 yıl	Şirket duyuruları	SEC Form 8-K

* ABD menkul kıymetleri için örnek, ABD dışı için eşdeğer düzenleyici formlar ve kaynaklar kullanılır.

Belirtilmediği sürece tüm finansal veriler yıllık bir döneme dayanmaktadır ancak üç ayda bir güncellenmektedir. Bu, İzleyen On İki Ay (TTM) veya Son On İki Ay (LTM) Verileri olarak bilinir. Buradan daha fazla bilgi edinin.

Analiz Modeli ve Kar Tanesi

Bu raporu oluşturmak için kullanılan analiz modelinin ayrıntıları Github sayfamızda mevcuttur, ayrıca raporlarımızın nasıl kullanılacağına dair kılavuzlarımız ve Youtube'da eğitimlerimiz bulunmaktadır.

Simply Wall St analiz modelini tasarlayan ve oluşturan dünya standartlarındaki ekip hakkında bilgi edinin.

Endüstri ve Sektör Metrikleri

Sektör ve bölüm metriklerimiz Simply Wall St tarafından her 6 saatte bir hesaplanmaktadır, sürecimizin ayrıntıları 'da mevcuttur.

Analist Kaynakları

IOL Chemicals and Pharmaceuticals Limited 3 Bu analistlerden 2, raporumuzun girdisi olarak kullanılan gelir veya kazanç tahminlerini sunmuştur. Analistlerin gönderimleri gün boyunca güncellenmektedir.

Analist	Kurum
null null	Antique Stockbroking Ltd.
Rohit Bhat	Batlivala & Karani Securities India Pvt. Ltd.
Kameswari V. S. Chavali	FirstCall Research

IOL Chemicals and Pharmaceuticals Gelecekteki Büyüme

Future kriter kontrolleri 4/6

Anahtar bilgiler

Gelecekteki son büyüme güncellemeleri

Price target decreased by 10% to ₹434

Price target decreased by 8.9% to ₹471

Price target increased by 15% to ₹517

Price target increased by 13% to ₹510

Price target increased to ₹575

Price target increased to ₹575

Recent updates

Investors Still Aren't Entirely Convinced By IOL Chemicals and Pharmaceuticals Limited's (NSE:IOLCP) Earnings Despite 26% Price Jump

Price target decreased by 10% to ₹434

IOL Chemicals and Pharmaceuticals (NSE:IOLCP) Has A Somewhat Strained Balance Sheet

Second quarter 2025 earnings released: EPS: ₹3.26 (vs ₹6.45 in 2Q 2024)

IOL Chemicals and Pharmaceuticals Limited to Report Q2, 2025 Results on Nov 14, 2024

IOL Chemicals and Pharmaceuticals Limited Announces Resignation of Vikas Vij as Chief Executive Officer, Effective 30 September 2024

A Piece Of The Puzzle Missing From IOL Chemicals and Pharmaceuticals Limited's (NSE:IOLCP) Share Price

Investor sentiment improves as stock rises 21%

IOL Chemicals and Pharmaceuticals Limited Announces Resignation of Sandhya Mehta as Independent Director

Full year 2024 earnings: EPS and revenues miss analyst expectations

IOL Chemicals and Pharmaceuticals Limited to Report Q1, 2025 Results on Aug 09, 2024

Price target decreased by 8.9% to ₹471

Is There An Opportunity With IOL Chemicals and Pharmaceuticals Limited's (NSE:IOLCP) 34% Undervaluation?

Full year 2024 earnings: EPS and revenues miss analyst expectations

IOL Chemicals and Pharmaceuticals Limited, Annual General Meeting, Aug 23, 2024

IOL Chemicals and Pharmaceuticals Limited to Report Q4, 2024 Results on May 14, 2024

Price target increased by 15% to ₹517

IOL Chemicals and Pharmaceuticals Limited Announces CDE, China Approved Metformin Hydrochloride

IOL Chemicals and Pharmaceuticals Limited Approves Closing of M/S Iol Global Limited, Uk, Wholly Owned Subsidiary of the Company

IOL Chemicals and Pharmaceuticals Limited to Report Q3, 2024 Results on Feb 06, 2024

Second quarter 2024 earnings released: EPS: ₹6.45 (vs ₹2.71 in 2Q 2023)

New major risk - Revenue and earnings growth

IOL Chemicals and Pharmaceuticals Limited to Report Q2, 2024 Results on Nov 08, 2023

Investor sentiment improves as stock rises 17%

Is IOL Chemicals and Pharmaceuticals (NSE:IOLCP) Using Too Much Debt?

IOL Chemicals and Pharmaceuticals Limited to Report Q1, 2024 Results on Aug 09, 2023

Full year 2023 earnings: EPS exceeds analyst expectations

IOL Chemicals and Pharmaceuticals (NSE:IOLCP) Has A Pretty Healthy Balance Sheet

Price target increased by 13% to ₹510

IOL Chemicals and Pharmaceuticals Receives Cep for Paracetamol to Export in European Market

Full year 2023 earnings: EPS exceeds analyst expectations

Investor sentiment improves as stock rises 19%

Upcoming dividend of ₹4.00 per share at 1.3% yield

IOL Chemicals and Pharmaceuticals (NSE:IOLCP) Will Pay A Dividend Of ₹4.00

Third quarter 2023 earnings released: EPS: ₹4.05 (vs ₹6.82 in 3Q 2022)

IOL Chemicals and Pharmaceuticals Limited Declares Interim Dividend for the Fiscal Year 2023, Payable Before 8 March 2023

IOL Chemicals and Pharmaceuticals Limited to Report Q3, 2023 Results on Feb 07, 2023

Investor sentiment improved over the past week

Second quarter 2023 earnings released: EPS: ₹2.71 (vs ₹5.26 in 2Q 2022)

Price target increased to ₹575

IOL Chemicals and Pharmaceuticals Limited Receives EDQM Certification to Supply Pantoprazole Sodium Sesquihydrate API in European Market

IOL Chemicals and Pharmaceuticals Limited to Report Q2, 2023 Results on Nov 14, 2022

Full year 2022 earnings released: EPS: ₹28.56 (vs ₹76.21 in FY 2021)

IOL Chemicals and Pharmaceuticals Limited to Report Q1, 2023 Results on Aug 09, 2022

Is IOL Chemicals and Pharmaceuticals (NSE:IOLCP) Using Too Much Debt?

Full year 2022 earnings released: EPS: ₹28.56 (vs ₹76.21 in FY 2021)

Now 20% undervalued

IOL Chemicals and Pharmaceuticals Limited Announces Executive Changes

IOL Chemicals and Pharmaceuticals Limited to Report Q4, 2022 Results on May 30, 2022

Calculating The Intrinsic Value Of IOL Chemicals and Pharmaceuticals Limited (NSE:IOLCP)

Price target increased to ₹575

IOL Chemicals and Pharmaceuticals Limited Commences the Commercial Production of 'Paracetamol' with Installed Capacity of 1,800 MTPA Along with Backward Integration of Para Amino Phenol (PAP) with Effect from 22 April 2022

Investor sentiment improved over the past week

Now 22% undervalued after recent price drop

Investor sentiment improved over the past week

Now 23% undervalued after recent price drop

Upcoming dividend of ₹4.00 per share

Third quarter 2022 earnings: Revenues and EPS in line with analyst expectations

IOL Chemicals and Pharmaceuticals Limited Declares Interim Dividend for the Financial Year 2021-222, Payable Before 5 March 2022

IOL Chemicals and Pharmaceuticals Limited to Report Q3, 2022 Results on Feb 04, 2022

Upcoming dividend of ₹2.00 per share

President of Project recently sold ₹3.5m worth of stock

First quarter 2022 earnings released: EPS ₹11.41 (vs ₹22.30 in 1Q 2021)

Full year 2021 earnings released: EPS ₹76.21 (vs ₹63.51 in FY 2020)

Do IOL Chemicals and Pharmaceuticals's (NSE:IOLCP) Earnings Warrant Your Attention?

Joint MD & Whole Time Director has left the company

IOL Chemicals and Pharmaceuticals Limited Appoints Sanjay Chaturvedi as Chief Executive Officer

Is IOL Chemicals and Pharmaceuticals Limited (NSE:IOLCP) An Attractive Dividend Stock?

Investor sentiment improved over the past week